Last updated: October 10, 2026
OptiMARK, the brand name for gadoversetamide, has moved from a differentiated gadolinium-based MRI contrast agent to a commercially marginal product. Its market position weakened because of generic substitution, competition from newer macrocyclic agents, safety concerns surrounding linear gadolinium compounds, and loss of meaningful patent or regulatory exclusivity. Public financial disclosures do not report standalone OptiMARK revenue, indicating that the product was not a material driver of its owner’s consolidated results.
What is OptiMARK and who commercialized gadoversetamide?
OptiMARK is an injectable gadolinium-based contrast agent used to enhance magnetic resonance imaging of the central nervous system, liver and other tissues. The active ingredient is gadoversetamide, a linear, nonionic gadolinium chelate.
The product was approved by the U.S. Food and Drug Administration in 1999 under New Drug Application 020793. Mallinckrodt was the principal U.S. commercial sponsor in the later life of the product. Earlier commercialization involved Mallinckrodt-related imaging businesses and predecessor corporate structures.
| Product |
Active ingredient |
Dosage form |
Primary use |
U.S. approval |
| OptiMARK |
Gadoversetamide |
Intravenous injection |
MRI contrast enhancement |
1999 |
| Product class |
Gadolinium-based contrast agent |
Injectable |
CNS, liver and other MRI applications |
Prescription product |
The product competed in a market that included Bayer’s Gadavist, Bracco’s ProHance and MultiHance, and Guerbet’s Dotarem. These products differed in chelate structure, indication breadth, formulation, institutional contracting and perceived safety profile.
When did OptiMARK lose exclusivity?
OptiMARK lost effective commercial exclusivity years ago. Its original small-molecule regulatory and patent protection no longer provides a meaningful barrier to competition.
What is the patent expiration status of gadoversetamide?
The key commercial protection for OptiMARK was not sustained by a current patent estate comparable to those supporting newer specialty pharmaceuticals. Public FDA materials do not identify an active, commercially significant Orange Book patent barrier that would prevent competing gadoversetamide products from entering the U.S. market.
The original patent portfolio associated with gadoversetamide and its formulation would have been filed in the 1990s. Standard U.S. patent terms for those filings generally expired no later than the mid-2010s, subject to patent-term adjustment, patent-term extension and specific filing dates. No continuing patent exclusivity has been identified as a current driver of OptiMARK pricing.
| Exclusivity category |
OptiMARK position |
| New chemical entity exclusivity |
Expired |
| Original composition patents |
Expired or commercially immaterial |
| Formulation patents |
No publicly material current barrier identified |
| Method-of-use patents |
No publicly material current barrier identified |
| Orphan-drug exclusivity |
Not applicable |
| Biologic exclusivity |
Not applicable |
| Current Orange Book protection |
No significant blocking position identified |
OptiMARK is a conventional small-molecule contrast agent, not a biologic. Biosimilar regulation therefore does not apply. Any competing product would proceed through a generic or abbreviated regulatory pathway rather than a biosimilar pathway.
What is the FDA regulatory status of OptiMARK?
OptiMARK was approved for intravenous administration during MRI procedures. Its principal regulatory risk came from the broader reassessment of gadolinium retention and the safety differences between linear and macrocyclic agents.
The FDA has required class-wide labeling addressing gadolinium retention in the body. The agency has stated that gadolinium retention occurs with all gadolinium-based contrast agents, although retention is higher with linear agents than with macrocyclic agents. The FDA has not concluded that gadolinium retention causes adverse health effects in patients with normal renal function, but it has required warnings and medication-guide information for the class.[2]
OptiMARK’s product labeling includes warnings concerning nephrogenic systemic fibrosis in patients with impaired elimination of gadolinium. The risk is concentrated in patients with severe renal impairment or acute kidney injury. These warnings affect hospital formulary decisions and favor products with stronger institutional safety profiles.
Was OptiMARK withdrawn from the European market?
European regulatory authorities took a stricter position on several linear gadolinium agents. The European Medicines Agency recommended restrictions, suspension or non-renewal of certain marketing authorizations because of gadolinium retention concerns. Gadoversetamide was among the linear agents affected by European regulatory action.
The European regulatory outcome reduced OptiMARK’s geographic commercial footprint and weakened its position in a market where MRI contrast agents are purchased through hospital tenders and national reimbursement systems. The product’s commercial opportunity became concentrated in remaining markets, including the United States and selected jurisdictions where the product retained authorization or supply capacity.[3]
How large was the OptiMARK market?
OptiMARK operated in a large but highly competitive MRI contrast market. Demand for MRI procedures continued to grow, but that growth did not translate proportionally into OptiMARK revenue.
Market expansion was constrained by four factors:
- Hospitals increasingly preferred macrocyclic agents.
- Generic and multisource competition reduced pricing power.
- Contrast agents were commonly purchased through institutional contracts.
- The product lacked a protected indication or delivery technology that could command a premium.
MRI contrast media are generally purchased as procedure-linked hospital products. Revenue depends on imaging volumes, formulary placement, supply reliability and contract pricing. Brand awareness among patients has little commercial relevance because physicians and hospitals select the agent.
What products competed with OptiMARK?
| Competitor |
Company |
Structural profile |
Commercial position |
| Gadavist |
Bayer |
Macrocyclic, nonionic |
Strong global hospital presence |
| Dotarem |
Guerbet |
Macrocyclic, ionic |
Expanding use and safety positioning |
| ProHance |
Bracco |
Macrocyclic, nonionic |
Established U.S. and global product |
| MultiHance |
Bracco |
Linear, ionic |
Broad historical indication base |
| Generic gadolinium agents |
Multiple manufacturers |
Varies |
Price-driven institutional competition |
Macrocyclic agents generally benefited from lower thermodynamic lability and stronger retention-related positioning than linear agents. That differentiation made it difficult for OptiMARK to compete on clinical perception even where the product remained approved.
What was OptiMARK’s financial trajectory?
OptiMARK revenue is not separately disclosed in the public financial reporting of its commercial owner. Mallinckrodt’s reporting has historically grouped products into broader business segments and did not provide a recurring standalone OptiMARK revenue line.
The available financial picture supports a mature-to-declining trajectory:
- Initial growth followed U.S. approval and adoption of gadolinium-enhanced MRI.
- Revenue later faced competition from established products with stronger hospital relationships.
- Price pressure increased as contrast media became procurement-driven.
- European regulatory restrictions reduced geographic reach.
- Gadolinium-retention concerns weakened demand for linear agents.
- OptiMARK did not appear to be a material contributor to consolidated corporate revenue in later reporting periods.
A precise annual revenue series cannot be derived from reported financial statements because OptiMARK was grouped with other products or was immaterial to segment-level disclosure. This is itself commercially relevant: the product lacked sufficient revenue scale to receive separate investor reporting.
Did OptiMARK generate material revenue for Mallinckrodt?
No public filing establishes OptiMARK as a material revenue driver. Mallinckrodt’s financial exposure was concentrated in larger specialty pharmaceutical and hospital products. OptiMARK was a legacy imaging product within a broader portfolio rather than a core growth asset.
Its economic value was likely based on residual cash flow from installed hospital demand and existing manufacturing capability, not on future pricing expansion or protected market growth.
What manufacturing and intellectual-property barriers affect OptiMARK?
Manufacturing complexity exists but does not create a durable competitive moat comparable to a patented drug-delivery system.
Gadoversetamide production requires:
- Synthesis of the chelating ligand;
- Control of gadolinium complexation;
- Removal of free gadolinium and process impurities;
- Sterile injectable manufacturing;
- Container-closure compatibility;
- Validated quality testing for elemental impurities and degradation products.
The product must meet strict standards for sterility, particulate matter, concentration, pH and dose uniformity. These requirements can limit the number of qualified suppliers. They do not, however, prevent competition indefinitely because the manufacturing process is based on an established small-molecule injectable platform.
The main barriers are regulatory validation, sterile manufacturing capacity, quality systems and hospital supply contracts. Patent protection is not the principal barrier.
Are there Paragraph IV challenges to OptiMARK?
No major, publicly prominent Paragraph IV litigation campaign involving OptiMARK has become a defining feature of the product’s market history. The commercial risk is different from that of a still-protected blockbuster.
Paragraph IV litigation matters when a generic applicant challenges an unexpired Orange Book patent. OptiMARK’s principal patents are understood to have expired or lost commercial significance, reducing the incentive for high-value patent litigation. Any current competitor would face regulatory and manufacturing execution issues more than an expensive patent thicket.
The absence of significant Paragraph IV litigation also reflects the product’s limited commercial upside. A generic entrant would enter a mature contrast-agent market with established competitors and contract-based pricing.
What patent litigation and settlement agreements affect OptiMARK?
No major active patent settlement agreement has been publicly identified as a current market determinant for OptiMARK. There is no widely reported settlement that delays generic entry or preserves an exclusive U.S. market position.
The absence of a material litigation barrier means that commercial outcomes depend on:
- Product availability;
- Hospital purchasing contracts;
- FDA approval of competing products;
- Labeling and renal-safety perceptions;
- Relative preference for macrocyclic agents;
- Net price after rebates and tenders.
What is the generic launch risk for OptiMARK?
Generic launch risk is high in principle because the product has limited patent protection and belongs to an established injectable category. The commercial opportunity for a new entrant is moderate to low because the market is price-sensitive and dominated by institutional purchasing.
A generic launch would likely produce one of three outcomes:
| Launch scenario |
Expected market effect |
| Single approved competitor |
Moderate price erosion and selective hospital substitution |
| Multiple generic entrants |
Rapid price compression and lower branded share |
| Macrocyclic substitution continues |
Limited recovery for linear gadoversetamide products |
OptiMARK’s brand could retain demand where physicians or hospitals prefer continuity, but that protection would be weak without a contractual, clinical or supply advantage.
How does OptiMARK compare with newer gadolinium agents?
OptiMARK is disadvantaged against Gadavist and Dotarem on current product positioning. The principal comparison is structural rather than patent-based.
| Factor |
OptiMARK |
Gadavist / Dotarem |
| Chelate type |
Linear |
Macrocyclic |
| Gadolinium retention perception |
Less favorable |
More favorable |
| Patent status |
Mature, expired |
Some products historically supported by more recent protection |
| Hospital positioning |
Legacy product |
Stronger contemporary adoption |
| Pricing power |
Limited |
Greater where clinically preferred |
| Growth outlook |
Declining or residual |
More resilient |
The shift toward macrocyclic agents is the central market dynamic. Even where OptiMARK remained technically suitable, hospitals had incentives to standardize on agents perceived to offer a better retention profile.
What is the outlook for OptiMARK?
OptiMARK’s outlook is defensive rather than growth-oriented. The product’s likely commercial value rests on residual sales, supply continuity and manufacturing economics. It lacks the main characteristics associated with a high-value pharmaceutical asset: active exclusivity, a differentiated delivery system, expanding indications, strong pricing power or a growing prescriber base.
Potential upside is limited to temporary supply shortages affecting competing agents, regional retention of formulary status, or cost-driven purchasing in markets where linear agents remain available. These factors would not reverse the broader competitive trend.
Key Takeaways
- OptiMARK is gadoversetamide, a linear gadolinium-based MRI contrast agent approved by the FDA in 1999.
- Its original patent and regulatory exclusivity have expired or no longer provide meaningful commercial protection.
- No material current Orange Book patent barrier or major Paragraph IV litigation campaign has been identified.
- FDA and European scrutiny of gadolinium retention weakened the position of linear agents.
- Macrocyclic competitors, including Gadavist, Dotarem and ProHance, have stronger contemporary market positioning.
- Mallinckrodt has not publicly reported standalone OptiMARK revenue, indicating limited financial materiality.
- The product’s value is based on residual hospital demand, manufacturing capability and supply continuity.
- Generic entry risk is structurally high, but the market’s mature economics limit the incentive for aggressive launch investment.
- Biosimilar risk does not apply because OptiMARK is a small-molecule contrast agent.
- The financial trajectory is best characterized as mature, declining and non-core.
FAQs About OptiMARK Market and Financial Outlook
Is OptiMARK still available in the United States?
OptiMARK’s U.S. commercial availability has been limited compared with newer gadolinium agents. Public FDA records and manufacturer supply information should be evaluated for current distribution status because approval, listing and active commercial supply are separate issues.
Does OptiMARK have an active U.S. patent?
No commercially significant active patent barrier is identified for OptiMARK. The product’s original protection dates from the 1990s and does not appear to support continuing exclusivity.
Is gadoversetamide a biosimilar?
No. Gadoversetamide is a synthetic small-molecule gadolinium contrast agent. Competitors would be regulated as generic or equivalent drug products, not biosimilars.
Which MRI contrast agent is commercially stronger than OptiMARK?
Gadavist, Dotarem and ProHance have stronger contemporary positioning because macrocyclic agents are generally preferred in the context of gadolinium-retention concerns and hospital formulary policy.
Can OptiMARK regain market share?
A sustained recovery is unlikely without a supply disruption affecting competitors, a new clinical differentiation, or a major change in hospital procurement. Its current commercial profile does not support a conventional growth trajectory.
References
- U.S. Food and Drug Administration. (1999). OptiMARK (gadoversetamide injection) prescribing information. FDA Drugs@FDA.
- U.S. Food and Drug Administration. (2018). FDA warns that gadolinium-based contrast agents are retained in the body; requires new class warnings. https://www.fda.gov
- European Medicines Agency. (2017). Gadolinium-containing contrast agents: referral under Article 31 of Directive 2001/83/EC. https://www.ema.europa.eu
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
- Mallinckrodt plc. (2014-2023). Annual reports and Form 10-K filings. U.S. Securities and Exchange Commission.
- American College of Radiology. (2024). ACR Manual on Contrast Media. American College of Radiology.
